PDGFRA Gene Mutation Testing: Identifying the Tumour Subgroup That KIT Testing Leaves Behind

Overview

Not every stromal tumour is driven by KIT, and the patients falling outside that group are precisely why PDGFRA genotyping is ordered. This piece approaches the assay as a population question: which tumours carry PDGFRA variants, where in the body those tumours tend to arise, and how a report should delineate the subgroup so that clinicians can act on it.

How It Works

PDGFRA belongs to the same receptor family as KIT and relays comparable growth signals through an intracellular kinase domain. Activating changes concentrate in three regions: exon 18, which encodes the activation loop and harbours the frequently observed D842V substitution; exon 12, covering the juxtamembrane region; and exon 14, spanning part of the kinase domain. Because these positions differ from the KIT hotspots, a KIT-only requisition returns a negative result in this subgroup even though a genuine receptor-level driver is present. Sequencing PDGFRA alongside or immediately after KIT closes that gap and reclassifies tumours previously labelled driver-unknown.

Indications

The subgroup worth prioritising is well characterised: stromal tumours reported as KIT wild-type, lesions arising in the stomach or omentum, and cases showing epithelioid morphology under the microscope. Where tissue is scarce and only one further test is realistic, these features identify the patients most likely to yield an informative PDGFRA result. Testing is used for molecular classification of the tumour and should be interpreted alongside histology rather than in isolation.

Specifications and Reporting

Formalin-fixed tissue is the standard input, with the laboratory confirming tumour cellularity before extraction. Coverage should span exons 12, 14 and 18, and the report ought to call out an exon 18 D842V finding explicitly rather than folding it into a generic exon 18 category, since that specific substitution defines a distinct subgroup within the subgroup. Variant allele fraction, predicted protein consequence and assay limit of detection complete a usable report.

Storage and Sourcing

Where PDGFRA follows a KIT request as reflex testing, the practical constraint is residual tissue rather than temperature. Confirm with the laboratory how many sections a single block can support and whether extracted DNA is retained for downstream requests, as re-cutting an exhausted block is often impossible. Blocks travel at ambient temperature, while retained nucleic acid is archived frozen. Agreeing reflex criteria in advance avoids a second specimen request that the patient may not be able to provide.

FAQ

Q: Which patients should be prioritised for PDGFRA analysis when tissue is limited? Prioritise KIT wild-type cases, gastric or omental primaries, and tumours with epithelioid features. These characteristics concentrate the diagnostic yield when only a single additional section can be spared.

Q: Why is the exon 18 D842V substitution singled out on reports? It is the most commonly encountered PDGFRA change and behaves as its own molecular category, so grouping it under a general exon 18 heading discards the distinction that makes the result actionable.

Q: Does a PDGFRA-positive finding alter how the tumour is classified? It moves the case from driver-unknown into a defined molecular subtype. The anatomical diagnosis stands, but the molecular classification and the population the patient belongs to both change.